Litcius/Paper detail

Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations

Wahida Rahman, Colleen H. Neal, Alexis V. Nees, Richard K. Brown

2020Radiology Imaging Cancer13 citationsDOIOpen Access PDF

Abstract

Nuclear medicine studies are often performed in patients with breast cancer; however, incidental radiotracer uptake in the breasts can be observed in patients with nonbreast malignancies. Benign and malignant lesions can be identified on planar, SPECT, and PET scans. This review will outline the molecular and radiographic imaging appearance of benign and malignant breast lesions on sestamibi scans, bone scans, radioiodine studies, as well as PET studies using fluorine 18 (18F) fluorodeoxyglucose, gallium 68 (68Ga) tetraazacyclododecane tetraacetic acid octreotate (or DOTATATE), 68Ga prostate-specific membrane antigen, and 18F-fluciclovine radiotracers. Recognizing these lesions at molecular and anatomic imaging is important to ensure accurate diagnosis and appropriate management. Keywords: Breast, Mammography, Molecular Imaging, PET/CT, Radionuclide Studies, SPECT/CT © RSNA, 2020

Topics & Concepts

MedicineNuclear medicineBreast cancerMammographyScintimammographyRadiologyBreast imagingMolecular imagingFluorodeoxyglucoseRadionuclide therapyPositron emission tomographyCancerInternal medicineIn vivoBiologyBiotechnologyMedical Imaging Techniques and ApplicationsRadiopharmaceutical Chemistry and ApplicationsMedical Imaging and Pathology Studies
Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations | Litcius